In particular, RTK/PI3K-Akt pathway inhibitors and CDK2 inhibitors have been evaluated in combination with CDK4/6 inhibitors very detailed in other tumor entities before [18, 19, 56, 57]. The gene discussed is AKT1; the disease is neoplasm.